OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences. Details for the presentations are as follows: Event: Healthcare Company Showcase hosted by Alliance Global PartnersDate and Time: Tuesday, May 21, 2024, at 3:20 PM ETWebcast Link Event: LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarDate and Time: Wednesd ...

财务数据和关键指标变化 - 公司在第一季度末拥有10.9亿美元现金 [26] - 研发费用保持稳定,而一般及管理费用较去年同期有所上升 [26] - 公司认为现有现金可以支持公司运营并达到多个潜在价值驱动的里程碑 [26] 各条业务线数据和关键指标变化 - 在DURIPANC联合用药试验中,Ampligen和durvalumab的组合治疗在第一剂量水平的安全性评估中表现良好,未出现严重不良事件或剂量限制性毒性 [8] - 在复发性卵巢癌联合用药试验中,Ampligen与pembrolizumab的组合疗法显示出强大的协同效果,客观缓解率达45%,远高于pembrolizumab单药的8%[20][21][22] - 公司正在等待AMP-518试验探索性生物标志物分析的结果,以确定下一步针对COVID-19后遗症疲劳的临床试验方案 [23][24] 各个市场数据和关键指标变化 - 未提及 公司战略和发展方向及行业竞争 - 公司认为Ampligen作为联合用药具有广谱适用于多种实体瘤的潜力,正在与制药公司洽谈商业化合作 [28][29][56][57] - 公司已获得Ampligen与PD-L1检查点抑制剂联合用药的协同疗效的专利保护 [59] - 公司正在优化Ampligen的制造工艺,以提高成本效率,为未来大规模临床试验和商业化做准备 [63][65][66] 管理层对经营环境和未来前景的评论 - 公司对Ampligen在多个适应症的临床数据持乐观态度,认为可以为患者提供有意义的治疗解决方案 [28][29][30] - 公司相信未来会有更多积极的安全性和疗效数据,有助于与潜在商业合作伙伴的洽谈 [29] 问答环节重要的提问和回答 问题1 **Unidentified Participant 提问** 询问复发性卵巢癌联合用药试验的患者人数和下一步计划 [33][34][35][36][37][38] **Thomas Equels 和 Christopher McAleer 回答** - 目前有21名患者纳入评估,这是一个中期报告,后续还会有更多患者入组 [35][37] - 这一数据显示Ampligen与化疗和免疫检查点抑制剂的联合疗法具有强大的协同作用,公司将利用这些数据推进商业化合作 [43][45] 问题2 **James Molloy 提问** 询问其他在研适应症的临床进展及商业化合作计划 [49][50][51][52][53][54][55][56][57][58][59][60] **Thomas Equels 回答** - 公司正在与制药公司合作开展多个联合用药临床试验,这些数据有助于降低大规模临床试验的风险 [50][51][52][56][57][58][59] - 公司已聘请专业的商业开发团队,正在与潜在合作伙伴接洽,希望利用这些临床数据推进商业化合作 [56][57][58][59] 问题3 **Ed Woo 提问** 询问Ampligen最新一批生产的情况,以及未来生产计划 [62][63][64][65][66] **Thomas Equels 回答** - 最新一批Ampligen生产顺利,成本有所上升但是可控 [63] - 未来两年内公司可能不需要再生产新批次,但如果启动大规模临床试验,则需要增加产能 [65][66] - 公司正在优化Ampligen的生产工艺,以提高效率和降低成本 [66]

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (details below ...

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (det ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organiza ...

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference ca ...

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dial ...

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, "We remain focused on operational execution and the successful continued production of our commercial-size ...

OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect, leading the investigator to conclude that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease. See further details on the study "Systemic Immune Checkpoint Blockade and ...

业绩总结 - 公司在2023年取得了显著进展，展示了日益增长的高度有前途、一致积极数据的成果[10] - 公司在肿瘤学领域的积极数据成为与专业肿瘤学业务发展公司Azenova合作的催化剂[12] - 公司成功扩大和确保了在肿瘤学领域的Ampligen专利资产[14] 未来展望 - 预计DURIPANC研究的第一阶段将在2024年夏季完成[30] - 公司相信Ampligen不仅仅是一种特定癌症的治疗方法，而是适用于多种类型的治疗[35] - 公司相信通过DURIPANC研究在胰腺癌中将证实Ampligen与免疫检查点抑制剂具有显著的协同效应[36] 新产品和新技术研发 - DURIPANC研究结合Ampligen和durvalumab作为FOLFIRINOX后的治疗[29] - Ampligen在不同实体瘤中的效果，通过与toll样受体3结合起作用[32] - Ampligen通过增加免疫生物标志物促使免疫系统攻击肿瘤[34] 市场扩张和并购 - 公司正在招聘和开设新站点，目前的站点仍在接受报名并筛选潜在候选人[28] - 欧洲预计在年底前将有人员参与治疗[50] - 美国由于标准护理的差异，导致招募困难[51] 负面信息 - 期望在2024年不再有高额的法律费用[71] - 美国有数百万人预计会患上严重的后COVID慢性疲劳症状[75] - 目前仅在美国就有大约400万潜在患者[75]